Core Viewpoint - The complex injection market is emerging as a new avenue for Chinese pharmaceutical companies to break into international markets, driven by high technical barriers and significant clinical value [1][2]. Group 1: Company Developments - Haizheng Pharmaceutical and Zhejiang Shengzhao Pharmaceutical Technology Co., Ltd. have established a joint venture focused on the development, production, and global commercialization of 11 complex injection products, including generics and modified new drugs [1]. - The chairman of Haizheng Pharmaceutical emphasized that complex injections are a key area for differentiated development and an important step in the company's internationalization strategy [1][2]. Group 2: Market Potential - According to Frost & Sullivan, the market size for complex injections in China is projected to reach 40.8 billion yuan by 2025 and 77.9 billion yuan by 2030, with a compound annual growth rate (CAGR) exceeding 13% [1]. - Unlike ordinary generics, complex injections maintain higher price levels due to their technical barriers, providing more growth opportunities for companies [1][2]. Group 3: Challenges in the Industry - The production of complex injections presents significant technical challenges, including high precision in process control and long-term stability verification, with few companies capable of large-scale industrial production [2][3]. - International market entry poses another challenge, as companies must navigate stringent regulatory requirements, particularly in markets like Europe and the U.S. [3]. - The competitive landscape includes companies from Israel, India, and the U.S., necessitating Chinese firms to establish differentiated advantages through technological breakthroughs and large-scale production [3].

证券日报网讯 11月6日晚间，海正药业发布公告称，近日，公司控股子公司浙江海正动物保健品有限公 司收到中华人民共和国农业农村部核准签发的复方制霉菌素软膏、托曲珠利混悬液兽药产品批准文号批 件。 （文章来源：证券日报） ...

证券代码：600267 证券简称：海正药业 公告编号：临 2025-67 号 浙江海正药业股份有限公司 关于子公司获得兽药产品批准文号批件的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，浙江海正药业股份有限公司（以下简称"公司"）控股子公司浙江海 正动物保健品有限公司（以下简称"海正动保公司"）收到中华人民共和国农业 农村部核准签发的复方制霉菌素软膏、托曲珠利混悬液兽药产品批准文号批件。 现就相关情况公告如下： 一、批件基本信息 （一）通用名称：复方制霉菌素软膏 兽药产品批准文号：兽药字 110803270 批准文号有效期：2025-09-05 至 2030-09-04 商品名称：尔特宁 含量规格：10g：制霉菌素 100 万单位+硫酸新霉素 3.5 万单位+氯菊酯 100mg+ 曲安奈德 10mg 企业名称：浙江海正动物保健品有限公司 生产地址：浙江省杭州市富阳区东洲街道高尔夫路 208 号 （二）托曲珠利混悬液 兽药产品批准文号：兽药字 110803301 批准文号有效期：2025-10-24 至 2030- ...

Core Viewpoint - Haizheng Pharmaceutical (600267.SH) has received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for two veterinary drug products, which will enhance its product line and market competitiveness in the veterinary medicine sector [1] Product Approval - The approved products include Compound Streptomycin Ointment, which is used to treat otitis externa in dogs and cats caused by bacteria sensitive to neomycin, fungi sensitive to streptomycin, and ear mites sensitive to chlorpyrifos [1] - The second product, Tocilizumab Suspension, is intended for the prevention of coccidiosis in piglets and calves [1] Strategic Implications - The approval of these veterinary drug products will enrich the company's veterinary medicine product line and structure, facilitating its strategic layout in the veterinary drug sector [1] - This development is expected to enhance the company's market competitiveness within the veterinary medicine industry [1]

Core Viewpoint - Haizheng Pharmaceutical (600267.SH) has received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for two veterinary drug products, which will enhance its product line and market competitiveness in the veterinary medicine sector [1] Group 1 - The company’s subsidiary, Zhejiang Haizheng Animal Health Products Co., Ltd., has been granted approval for the compound streptomycin ointment and torquatozole suspension veterinary drug products [1] - The approval will enrich the company's veterinary drug product line and structure, supporting its strategic layout in the veterinary medicine sector [1] - This development is expected to improve the company's market competitiveness in the veterinary drug market [1]

Core Viewpoint - Haizheng Pharmaceutical announced that its subsidiary, Haizheng Animal Health, received approval from the Ministry of Agriculture and Rural Affairs for two veterinary drug products, which will enhance the company's product line in animal medicine [1] Group 1: Product Approvals - The approved products include Compound Streptomycin Ointment, valid from September 5, 2025, to September 4, 2030, for treating external ear infections in dogs and cats [1] - The second product, Tocilizumab Suspension, is approved for use from October 24, 2025, to October 23, 2030, aimed at preventing coccidiosis in piglets and calves [1] Group 2: Market Impact - The approval of these products will enrich the company's veterinary drug portfolio, although the market launch and sales are subject to uncertainties related to policies and market conditions [1]

Core Viewpoint - Haizheng Pharmaceutical (600267.SH) has received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for its veterinary drug products, which will enhance its product line and market competitiveness in the veterinary sector [1] Group 1 - Haizheng Pharmaceutical's subsidiary, Zhejiang Haizheng Animal Health Products Co., Ltd., has obtained approval for the compound griseofulvin ointment and torasemide suspension veterinary drug products [1] - The approval will enrich the company's veterinary drug product line and structure [1] - This development is expected to further promote the company's strategic layout in the veterinary drug sector [1]

Meeting Overview - The company will hold its second extraordinary general meeting of shareholders in 2025 on November 12, 2025, at 1:00 PM [2] - The meeting will be convened by the Board of Directors following the eighth meeting of the tenth Board [2] Voting Method - The voting will be conducted through a combination of on-site and online voting [3] - On-site voting will take place at the company's conference room located at 46 Waisha Road, Jiaojiang District, Taizhou City, Zhejiang Province [3] - Online voting will be available via the Shanghai Stock Exchange's shareholder meeting voting system on the same day, with specific time slots for trading system and internet platform voting [3] Meeting Agenda - The meeting will review proposals that have already been approved by the eighth meeting of the tenth Board of Directors [6] - There are no special resolutions or proposals requiring separate voting for minority investors [7] Attendance - Shareholders registered with the China Securities Depository and Clearing Corporation Limited Shanghai Branch after the close of trading on the registration date are entitled to attend the meeting [10] - The meeting will also be attended by the company's directors, senior management, and appointed lawyers [11][12] Registration Process - Registration for attendance requires specific documentation depending on the type of shareholder, with a registration period set for November 10, 2025 [13][14] - Remote shareholders can register via mail or fax [15] Additional Information - The meeting will last half a day, and attendees are responsible for their own travel and accommodation [16] - The company will utilize a reminder service to notify shareholders about the meeting and voting options [16] - Contact information for inquiries is provided, including phone and fax numbers [16]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600267 证券简称：海正药业 公告编号：临2025-66号 浙江海正药业股份有限公司 关于召开2025年第二次临时股东会的提示性公告 重要内容提示： 浙江海正药业股份有限公司（以下简称"公司"）于2025年10月28日在《中国 证券报》《上海证券报》《证券时报》和上海证券交易所网站（www.sse.com.cn） 上刊登了《浙江海正药业股份有限公司关于召开2025年第二次临时股东会的通 知》（公告编号：临2025-63号）。本次股东会采用现场和网络投票相结合的方 式召开，现发布本次临时股东会提示性公告。 一、 召开会议的基本情况 (一)股东会类型和届次 2025年第二次临时股东会 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 11 月 12 日 13 点 00 分 召开地点：浙江海正药业股份有限公司会议室（台州市椒江区外沙路 46 号） (五)网络投票的系统、起止日期和投票时间。 股东会召开日期：2025年11月12日 本次股东会采用的网络投票 ...

浙江海正药业股份有限公司 2025 年第二次临时股东会会议资料 浙江海正药业股份有限公司 2025 年第二次临时股东会会议资料 二○二五年十一月十二日 浙江海正药业股份有限公司 2025 年第二次临时股东会会议资料 会议议程 时间：2025 年 11 月 12 日（周三）13:00，会期半天 地点：浙江海正药业股份有限公司（以下简称"公司"或"海正药业"）会议室（台 州市椒江区外沙路 46 号） 主要议程： 一、宣布会议开始并宣布到会代表资格审查结果 二、审议下列议案 | 序号 | 议案名称 | | --- | --- | | 非累积投票议案 | | | 1 | 关于拟参与浙江圣兆药物科技股份有限公司股票定向发行及与其共同投 | | | 资设立复杂注射剂合资公司的议案 | 上述议案已经公司第十届董事会第八次会议审议通过，具体内容详见 2025 年 10 月 28 日的《中国证券报》《上海证券报》《证券时报》及上海证券交易所网站 （www.sse.com.cn）。 三、股东及其授权代表发言及答疑 四、对上述各议案进行投票表决 五、统计有效表决票 六、宣布表决结果 2 1、总监票组织监票小组 2、股东及股东代表投 ...